15 June 2026
QV Bioelectronics Marks World Brain Tumour Day with Major Milestone for SHIELD Study
Last week on World Brain Tumour Day, QV Bioelectronics reached an important milestone in the development of GRACE, the world's first fully implantable Tumour Treating […]
9 April 2026
Eduard Fedorov joins QV Bioelectronics as Senior Physicist
We’re excited to welcome Eduard Fedorov to QV Bioelectronics!Eduard is a seasoned physicist and technology leader, with over 15 years of interdisciplinary experience spanning advanced […]
23 March 2026
QV Bioelectronics Attends LSI USA 2026 in Dana Point
QV Bioelectronics was pleased to attend LSI USA 2026 in Dana Point, California, one of the leading global gatherings for emerging medtech companies, investors, and […]
17 March 2026
Leadership Update
QV Bioelectronics is pleased to announce a leadership transition as the company enters its next phase of growth and clinical development. Carl Daintree has assumed […]
21 January 2026
QV Bioelectronics secures £4.5m to advance implantable brain cancer therapy into first-in-human studies
QV Bioelectronics has secured £4.5m in investment and grant funding to support the next phase of development of GRACE, its world-first fully implantable electric field […]
7 May 2025
Backing Secured to Prepare First Trial of Implanted Electric Field Therapy
QV Bioelectronics, developer of a first-in-class implanted Electric Field Therapy (EFT) device for brain tumours, has been awarded a £1.26 million grant under the highly […]
Interested in Receiving our Press Releases?